RT Journal Article
SR Electronic
T1 Novel prefrontal synthesis intervention improves language in children with autism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.10.19014159
DO 10.1101/2019.12.10.19014159
A1 Vyshedskiy, Andrey
A1 Khokhlovich, Edward
A1 Dunn, Rita
A1 Faisman, Alexander
A1 Elgart, Jonah
A1 Lokshina, Lisa
A1 Gankin, Yuriy
A1 Ostrovsky, Simone
A1 deTorres, Lauren
A1 Edelson, Stephen M
A1 Ilyinskii, Petr O
YR 2020
UL http://medrxiv.org/content/early/2020/10/02/2019.12.10.19014159.abstract
AB Prefrontal synthesis (PFS) is defined as the ability to juxtapose mental objects at will. Paralysis of PFS may be responsible for the lack of comprehension of spatial prepositions, semantically-reversible sentences, and recursive sentences observed in 30 to 40% of individuals with ASD. In this report we present data from a three-year-long clinical trial of 6,454 ASD children aged 2-12 years, which were administered a PFS-targeting intervention. Tablet-based verbal and nonverbal exercises emphasizing mental-juxtaposition-of-objects were organized into an application called Mental Imagery Therapy for Autism (MITA). The test group included participants who completed more than one thousand exercises and made no more than one error per exercise. The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation. The test group showed 1.7-fold improvement in receptive language score vs. control group (p=0.0002) and 1.4-fold improvement in expressive language (p=0.0144). No statistically significant change was detected in other subscales not targeted by the exercises. These findings show that language acquisition improves by training PFS and warrants further investigation of the PFS-targeting intervention in a randomized controlled study.Competing Interest StatementThis study was self-funded. AV, EK, POI, RD, AF, JE, LL, and YG are partners in ImagiRation limited liability partnership, the developer of MITA.Clinical TrialNCT02708290Funding StatementThis study was self-funded.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified raw data from this manuscript are available from the corresponding author upon reasonable request.